

<b>Substitute for form 1449a/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 1 of 2	<b>Confirmation Number</b>	9232
	<b>Application Number</b>	10/805,722
	<b>Filing Date</b>	March 22, 2004
	<b>First Named Inventor</b>	Robert Falotico
	<b>Group Art Unit</b>	1615
	<b>Examiner Name</b>	AZPURU, CARLOS A.
	<b>Attorney Docket Number</b>	CRD5070USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/C.A./		BEUTLER, E., <i>Cladribine (2-chlorodeoxyadenosine)</i> , The Lancet, Vol. 340, 1992, pp. 952-956.	
		CARSON, D. et al., <i>DNA Strand Breaks, NAD Metabolism, and Programmed Cell Death</i> , Exp. Cell Research, 164, 1986, pp. 273-281	
		DEORANNE, C.F. et al., <i>Histone Deacetylases Inhibitors as Anti-angiogenic Agents Altering Vascular Endothelial Growth Factor Signaling</i> , Oncogene, 21, 2002, pp. 427-436.	
		SCHWARTZ, S.M. et al., <i>Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery</i> , Circ. Res., 56, 1985, pp. 139-145.	
		SETO, S., et al., <i>Mechanism of Deoxyadenosine and 2-Chlorodeoxyadenosine Toxicity to Nondividing Human Lymphocytes</i> , J. Clin. Invest., Vol. 75, 1985, pp. 377-383.	
/C.A./		WILEY, J., <i>Fluorocarbon Elastomers, Modern Fluoropolymers</i> , Wiley Series in Polymer Science, 1997, pp. 71-90.	
		WOO, S.H., <i>Structurally Simple Trichostatin A-like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors</i> , J. of Medicinal Chemistry, 45(13), 2002, pp. 2877-2885.	

<b>Examiner Signature</b>	/Carlos Azpuru/	<b>Date Considered</b>	05/14/2009
---------------------------	-----------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450